AEON Biopharma reported a net loss of $1.2 million for the second quarter ended June 30, 2026, driven by $5.9 million in operating expenses. The company completed an underwritten public offering in July 2026, generating approximately $13.6 million in net proceeds and up to $34.0 million in potential gross proceeds from milestone warrants. These funds extend the cash runway into the first quarter of 2027. AEON also restored compliance with NYSE American listing requirements on August 3, 2026. The company is advancing ABP-450 as a biosimilar to BOTOX for therapeutic use and expects FDA feedback in the second half of 2026 regarding clinical pharmacology and comparative study requirements. AEON Biopharma operates in the biopharmaceutical industry, developing biosimilars.
